Fresenius Pushes Kabi Even Higher As Former Sandoz Exec Named CEO
Kabi Scours For Divestments, ‘Business Not Understood Or Appreciated’
The Fresenius group spoke at length about its core Fresenius Kabi business during the company’s year-end financial call, not least its under pressure IV drugs in the US.
You may also be interested in...
Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.
After a meeting in Vienna, the IGBA’s CEO advisory committee has outlined four key areas in which action is needed to bolster supply-chain security and ensure pandemic prevention, preparedness and response.